5/14
08:15 am
pali
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/14
08:05 am
pali
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
5/7
08:37 am
pali
Palisade Bio Appoints Margery Fischbein to its Board of Directors [Yahoo! Finance]
Medium
Report
Palisade Bio Appoints Margery Fischbein to its Board of Directors [Yahoo! Finance]
5/7
08:30 am
pali
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Medium
Report
Palisade Bio Appoints Margery Fischbein to its Board of Directors
5/7
07:39 am
pali
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules [Yahoo! Finance]
Medium
Report
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules [Yahoo! Finance]
5/7
07:30 am
pali
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Medium
Report
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
5/2
08:43 am
pali
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules [Yahoo! Finance]
Medium
Report
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules [Yahoo! Finance]
5/2
08:30 am
pali
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
High
Report
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
5/1
01:31 pm
pali
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Low
Report
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
5/1
08:39 am
pali
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) [Yahoo! Finance]
High
Report
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) [Yahoo! Finance]
5/1
08:30 am
pali
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
Medium
Report
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
4/23
08:47 am
pali
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach [Yahoo! Finance]
Medium
Report
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach [Yahoo! Finance]
4/23
08:30 am
pali
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
High
Report
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
4/16
02:03 pm
pali
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Medium
Report
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
4/16
09:15 am
pali
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool [Yahoo! Finance]
High
Report
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool [Yahoo! Finance]
4/16
08:30 am
pali
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
High
Report
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
4/11
09:20 am
pali
Palisade Bio to Participate in the Virtual Investor Lunch Break Event [Yahoo! Finance]
Low
Report
Palisade Bio to Participate in the Virtual Investor Lunch Break Event [Yahoo! Finance]
4/11
09:15 am
pali
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Low
Report
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
4/10
08:21 am
pali
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™ [Yahoo! Finance]
High
Report
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™ [Yahoo! Finance]
4/10
08:15 am
pali
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
High
Report
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
4/3
05:35 pm
pali
Palisade Bio Announces 1-for-15 Reverse Stock Split [Yahoo! Finance]
Low
Report
Palisade Bio Announces 1-for-15 Reverse Stock Split [Yahoo! Finance]
4/3
05:30 pm
pali
Palisade Bio Announces 1-for-15 Reverse Stock Split
Low
Report
Palisade Bio Announces 1-for-15 Reverse Stock Split
3/27
08:21 am
pali
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/27
08:00 am
pali
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Medium
Report
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update